Salarius Pharmaceuticals, Inc.
SLRX
$0.698
-$0.0348-4.75%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -5.58M | -4.99M | -6.46M | -8.92M | -12.54M |
| Total Depreciation and Amortization | 4.40K | 4.40K | 8.90K | 9.50K | 10.10K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 273.70K | 308.10K | 490.80K | 529.10K | 654.90K |
| Change in Net Operating Assets | 772.30K | -612.90K | -1.72M | -2.65M | -968.40K |
| Cash from Operations | -4.53M | -5.29M | -7.69M | -11.03M | -12.85M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -466.60K | -529.00K | -570.60K | -453.70K | -280.90K |
| Issuance of Common Stock | 1.53M | 1.53M | 88.70K | 6.68M | 7.02M |
| Repurchase of Common Stock | -- | 0.00 | -100.40K | -100.40K | -100.40K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1.06M | 997.50K | -582.20K | 6.13M | 6.64M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -3.47M | -4.30M | -8.27M | -4.90M | -6.21M |